Background: The accurate assessment of individual risk can be of great value to guiding and facilitating the prevention of atherosclerotic cardiovascular disease (ASCVD). However, prediction models in common use were formulated primarily in white populations. The China-PAR project (Prediction for ASCVD Risk in China) is aimed at developing and validating 10-year risk prediction equations for ASCVD from 4 contemporary Chinese cohorts.
Methods: Two prospective studies followed up together with a unified protocol were used as the derivation cohort to develop 10-year ASCVD risk equations in 21 320 Chinese participants. The external validation was evaluated in 2 independent Chinese cohorts with 14 123 and 70 838 participants. Furthermore, model performance was compared with the Pooled Cohort Equations reported in the American College of Cardiology/American Heart Association guideline.
Results: Over 12 years of follow-up in the derivation cohort with 21 320 Chinese participants, 1048 subjects developed a first ASCVD event. Sex-specific equations had C statistics of 0.794 (95% confidence interval, 0.775-0.814) for men and 0.811 (95% confidence interval, 0.787-0.835) for women. The predicted rates were similar to the observed rates, as indicated by a calibration χ of 13.1 for men (P=0.16) and 12.8 for women (P=0.17). Good internal and external validations of our equations were achieved in subsequent analyses. Compared with the Chinese equations, the Pooled Cohort Equations had lower C statistics and much higher calibration χ values in men.
Conclusions: Our project developed effective tools with good performance for 10-year ASCVD risk prediction among a Chinese population that will help to improve the primary prevention and management of cardiovascular disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1161/CIRCULATIONAHA.116.022367 | DOI Listing |
R I Med J (2013)
February 2025
Division of Cardiology, Department of Medicine, Brown University, Providence RI.
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality worldwide. This review explores the evolving evidence base surrounding ASCVD prevention, particularly regarding nontraditional biomarkers, risk scores, and cardiovascular imaging modalities. Additionally, this review examines cardiovascular risk scores, including the PREVENT and MESA-CHD scores, which incorporate both traditional and nontraditional factors, thereby aspiring to offer a more equitable and precise risk assessment.
View Article and Find Full Text PDFAm J Prev Cardiol
March 2025
UT Southwestern Medical Center, Department of Medicine, Division of Cardiology, TX, USA.
Objective: Lowering lipid to reach guideline-indicated goals significantly reduces cardiovascular outcomes in very-high-risk (VHR) patients with atherosclerotic cardiovascular disease (ASCVD) and type 2 diabetes (DM2). How well VHR patients currently achieve these goals in community practice is unknown.
Methods: VHR patients with ASCVD and DM2 were identified across 14 US healthcare systems using electronic health records between 1/1/2021-12/31/2022.
Arch Endocrinol Metab
January 2025
Unidade de Endocrinologia Ginecológica Hospital de Clínicas de Porto Alegre Divisão de Endocrinologia Porto AlegreRS Brasil Unidade de Endocrinologia Ginecológica, Divisão de Endocrinologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brasil.
Objective: To assess the genotypic and allelic distribution of the rs10046 polymorphism in the gene and evaluate whether this aromatase gene variant is associated with cardiovascular risk in postmenopausal women.
Materials And Methods: This cross-sectional study analyzed repository-stored samples from 370 postmenopausal women aged 44-72 years. Clinical, metabolic, and hormonal data were collected.
Sci Rep
January 2025
Gachon Medical Research Institute, Gachon Biomedical Convergence Institute, Gachon University Gil Medical Center, College of Medicine, Gachon University, Incheon, 21565, Republic of Korea.
The benefit of aspirin in primary prevention for atherosclerotic cardiovascular diseases (ASCVD) is questionable due to bleeding complications. We analyzed the Korean National Health Insurance data to compare the efficacy and overall bleeding of sarpogrelate, an antiplatelet agent with lower bleeding risk, versus aspirin in high-/very-high-risk diabetic populations without prior ASCVD. The primary endpoint was net adverse clinical events (NACE), defined as a composite of efficacy and overall bleeding.
View Article and Find Full Text PDFEur J Prev Cardiol
January 2025
Amsterdam UMC location Vrije Universiteit Amsterdam, Department of General Practice Medicine, De Boelelaan 1117, Amsterdam, The Netherlands.
Aims: To investigate if adding ECG abnormalities as a predictor improves the performance of incident CVD-risk prediction models for people with type 2 diabetes (T2D).
Methods: We evaluated the four major prediction models that are recommended by the guidelines of the American College of Cardiology/American Heart Association and European Society of Cardiology, in 11,224 people with T2D without CVD (coronary heart disease, heart failure, stroke, thrombosis) from the Hoorn Diabetes Care System cohort (1998-2018). Baseline measurements included CVD-risk factors and ECG recordings coded according to the Minnesota Classification as no, minor or major abnormalities.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!